Completed
NA
INTERVENTIONAL
NCT00711620
Efficacy of Thymosin alpha1 for Severe Sepsis
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.
Detailed Description
Severe sepsis is a disease of infectious origin with a high risk of death. Over the past decade, thymosin alpha1 have already provided clinicians with additional weapon in the fight against infectious diseases, but it is unknown whether thymosin alpha1 is effective in treating severe sepsis.
Interventions
Name:
Thymosin alpha 1
Type:
DRUG
Description:
1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Primary Outcomes
Measure:
28-day Mortality
TimeFrame:
28 days
Description:
The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion.
Trial Information
NCT ID
NCT00711620
Status
Completed
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Sun Yat-sen University
Last Updated
December 15, 2025